Novel HADHA Mutation Causes Mitochondrial Protein Deficiency and Neuromuscular Disease | Chapter 4 | Advanced Concepts in Medicine and Medical Research Vol. 11

Mitochondrial trifunctional protein inadequacy (MTP deficiency) is a rare inherited disorder affecting oxidation of long-chain oily acids. It typically causes severe neonatal symptoms like courage/liver disease, hypoglycemia, and metabolic acidosis. It can still gradually present with minor neuropathy, episodic rhabdomyolysis, and vision deficit. Progressive peripheral neuropathy is an irrevocable complication. We report a unique case of a 5-period-old boy with slowly decaying limb weakness. Hereditary analysis revealed a novel homozygous HADHA metamorphosis causing his MTP inadequacy, representing the first described incident in India. Exome sequencing comprehensively analyzed genes. The patient shown sensorimotor axonal neuropathy with secondary muscle disintegration, reflecting neuromyopathy. Our study provides further awareness into genotype-phenotype correlations in mitochondrial trifunctional protein deficiency.

Author(s) Details:

Amit Vatkar,
Department of Pediatrics, Seth V.C. Gandhi and M.A. Vora Municipal Rajawadi Hospital, Mumbai, Maharashtra, India.

S. Joshi Nishigandha,
Department of Pediatrics, Seth V.C. Gandhi and M.A. Vora Municipal Rajawadi Hospital, Mumbai, Maharashtra, India.

Smita Patil,
Department of Pediatrics, Seth V.C. Gandhi and M.A. Vora Municipal Rajawadi Hospital, Mumbai, Maharashtra, India.

Mumtaz Shariff,
Department of Pediatrics, D.Y. Patil Hospital, Mumbai, Maharashtra, India.

Please see the link here: https://stm.bookpi.org/ACMMR-V11/article/view/12887

The Potential Role of Neuroplasticity in the Treatment of Paraneoplastic Neuropathy with Scrambler Therapy | Chapter 6 | Current Progress in Medicine and Medical Research Vol. 9

With an occurrence of up to 8%, paraneoplastic syndromes are comparatively uncommon, but are an frequently frustrating result for cancer patients accompanying significant associations on quality of existence [1] Paraneoplastic sensory neuropathic syndromes are between the more common paraneoplastic syndromes, and can present in a sort of ways containing pain, numbness, and/or pruritus. It maybe a particularly difficult condition to accomplish as it often does not resolve regardless of successful situation of cancer. Scrambler Therapy is a non-obtrusive neuromodulation therapy namely believed to take over the pain signals involved in neuropathic syndromes accompanying “non-pain information” through the process of neuroplasticity. Scrambler Therapy is approved for incessant and neuropathic pain, and has been proved to have few, if any, reactions. We report here a case of paraneoplastic neuropathy, giving with pain and pruritus, that returned to Scrambler Therapy without aftereffects or complications.

Author(s) Details:

Tyler K. Murphy,
Medicine, Johns Hopkins University School of Medicine, Baltimore, USA.

Please see the link here: https://stm.bookpi.org/CPMMR-V9/article/view/11690

The Efficacy of Pyridoxine for Treatment of Neuropathy and Neurotoxic Side Effects in Rifampicin-Resistant Tuberculosis | Chapter 8 | Current Innovations in Disease and Health Research Vol. 4

 This phase assess the effectiveness of merging Pyridoxine (Vitamin B6) in treatment menus for preventing and treating minor neuropathy and neurotoxic adverse occurrences associated with Rifampicin-resistant infection (RR-TB) medications. A orderly review was conducted to evaluate the practice of executing pyridoxine in the prevention and/or situation of neuropathy and neurotoxicity related to RR-TB treatment. The study public consisted of cases with RR-TB who knowing neuropathy and/or neurotoxicity due to RR-TB regimes and received pyridoxine.Contradictory evidence was found concerning the use of pyridoxine in preventing or medicating neurotoxicity caused by cycloserine in RR-TB treatment. Additionally, pyridoxine acted not demonstrate a protective effect against neuropathy and/or neurotoxicity guide other RR-TB procedures lacking isoniazid. Our review indicated that interrupting or withholding cures such as linezolid, cycloserine, thioamides, fluoroquinolones, and ethambutol, known to cause neuropathy or neurotoxicity, was more effective than utilizing pyridoxine in halting the progression of syndromes, and in certain cases, even developed in symptom reversal over period. Furthermore, comorbidities that predispose ruling class to developing these adverse occurrences should be usually assessed and, when elicited, sufficiently managed.

Author(s) Details:

Joseph G. Kariuki,
Master of International Health, Charité – Universitätsmedizin Berlin, Germany.

Symon M. Kariuki,
Department of Tropical Neurosciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Phuti Angel,
Master of International Health, Charite - Universitätsmedizin Berlin, Germany.

Please see the link here: https://stm.bookpi.org/CIDHR-V4/article/view/11451

Study about Diabetic Neuropathy: Current Concept and Future Perspectives | Chapter 12 | Current Aspects in Pharmaceutical Research and Development Vol. 5

 In underdeveloped countries, diabetic neuropathy (DN) is one of the leading causes of blindness. Currently, one out of every five diabetic patients may be diagnosed with DN. In clinical practise and clinical trials, assessing DN has proven to be complex and challenging. Unfortunately, there is no one treatment for neuropathic alterations or pain relief that can be used to avoid or reverse them. Intensive glucose control, risk factor management, and genetically configuration are the three main therapy options for diabetic neuropathy. Amitriptyline and duloxetine have now been discovered as effective pain relievers in DN. However, there is an increasing need for research to analyse the most effective medications and combinations for the treatment of DN in order to maximise pain alleviation and improve quality of life. Nav antagonists, N-type calcium channel blockers, NGF antibodies, and angiotensin II type 2 receptor antagonists are all viable options for DN treatment. Modifying risk factors, genetics, and treatment of DN are all discussed in this topic.

Author(S) Details

D. Nagasamy Venkatesh
Department of Pharmaceutics, JSS College of Pharmacy, Ooty – 643 001, Tamil Nadu, India.

S. D. Shanmugakumar
Jyothishmathi Institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telanagana – 505481, India.

View Book:- https://stm.bookpi.org/CAPRD-V5/article/view/4947

Determining the Relationship between Platelet Indices and Microvascular Complications in Type 2 Diabetic Patients | Chapter 22 | Recent Developments in Medicine and Medical Research Vol. 6

 Diabetes is a prevalent metabolic illness that affects the entire world's population and causes a large amount of morbidity and mortality, owing to its micro- and macrovascular consequences. The link between platelet indices such as mean platelet volume, platelet distribution width, plateletcrit, and total platelet count in diabetic patients with and without microvascular issues is investigated in this study. Until 2019, this review of the literature was conducted utilising a public access website such as PubMed, Google Scholar, or Medline databases. Patients with macrovascular issues and those using drugs that alter platelet indices were the main exclusion criteria in the investigations. These articles were all scrutinised. Platelet indices such as mean platelet volume and platelet distribution width were significantly higher in those with microvascular complications, especially Diabetic Nephropathy and Diabetic Retinopathy, when compared to those without. Changes in platelet indices were found to be significantly associated to diabetic microvascular issues. As a result, these characteristics can be used to track and predict the risk of microvascular complications.

Author(S) Details

Siva Ranganathan Green
Department of Medicine, Mahatma Gandhi Medical College, Sri Balaji Vidyapeeth University (Deemed to be), Pondicherry, India.

Subashini Subramanian
Department of Medicine, Mahatma Gandhi Medical College, Sri Balaji Vidyapeeth University (Deemed to be), Pondicherry, India.

Lokesh Shanmugam
Department of Medicine, Mahatma Gandhi Medical College, Sri Balaji Vidyapeeth University (Deemed to be), Pondicherry, India.

View Book:- https://stm.bookpi.org/RDMMR-V6/article/view/4548